Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy.

Journal article

Little is known of the changes in human immunodeficiency virus type 1 (HIV-1)-specific effector cytotoxic T lymphocytes (CTL) after potent antiretroviral therapy. Using HLA/peptide tetrameric complexes, we show that after starting treatment, there are early rapid fluctuations in the HIV-1-specific CTL response which last 1 to 2 weeks. These fluctuations are followed by an exponential decay (median half-life, 45 days) of HIV-1-specific CTL which continues while viremia remains undetectable. These data have implications for the immunological control of drug-resistant virus.

Authors: Ogg, G; Jin, X; Bonhoeffer, S; Moss, P; Nowak, M

• Publication status: Published
• Journal: Journal of virology
• Volume: 73
• Issue: 1
• Pages: 797-800
• Publication date: 1999-01-01
• EISSN: 1098-5514
• ISSN: 0022-538X
• Language: English
• Keywords: ADP-ribosyl Cyclase; T-Lymphocytes, Cytotoxic; Anti-HIV Agents; Humans; Drug Therapy, Combination; Antigens, CD38; Antigens, CD; HIV-1; NAD+ Nucleosidase; Membrane Glycoproteins; Acquired Immunodeficiency Syndrome; Antigens, Differentiation